Author name: Leonardo Arias

The year kicked off with a handful of acquisitions from top companies. Dealmaking has since slowed amid economic uncertainty but could be poised for a rebound.

The former Masimo executive will lead strategy development to support the transition to BD’s revised business structure over the next several months.

The first-of-its-kind research suggests vertical consolidation is being driven by the potential for profits in nudging MA members to owned clinics, researchers said.

CVS plans to appeal the judgment, which comes after a jury ruled that its long-term care pharmacy benefits manager illegally charged Medicare, Medicaid and Tricare for prescription drugs for almost a decade.

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR Pharmaceuticals for use in up to five of Alexion’s gene therapies.

In the second biggest acquisition of the year, Merck gains the commercial COPD drug Ohtuvayre, which could help offset the loss of revenue when Keytruda’s patent expires later this decade.

Digital health companies that used AI as a core part of their offerings raised more money on average in the first half of 2025 compared with their non-AI counterparts.

Un nuevo estudio revela cómo afectó el cambio climático global de hace más de 12.000 años a las poblaciones humanas prehistóricas.   La investigación ha sido liderada desde la Universidad de Colonia en Alemania y ha contado con la participaci&o …

Leerink Partners called the announcement a ‘positive’ given the delayed timeframe and the uncertainty that the administration will implement tariffs at all.

The high court’s order blocks a May decision by a California court that temporarily blocked the efforts of Health Secretary Robert F. Kennedy Jr. to drastically reduce the size of his agency’s workforce.